Phase 4 N=20 Understanding Experimentally Induced Hot Flushes
Hot Flashes
Primary: Percent Change in Objective Sleep Efficiency — -2.6; 4.2 percent change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=37 Neuropeptide Treatment for Hot Flushes During the Menopause
Menopausal Flushing
Primary: Total Number of Hot Flushes During the Final Week of Each 4 Weeks Treatment Period — 19.35; 49.01 hot flushes — p=<0.0001
Phase 2 N=356 Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
Menopausal and Female Climacteric States
Primary: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) and Number of Participants With Mild, Moderate and Severe AE — 54; 52; 45; 51 Participants
Phase 2 N=141 Flushing Reduction Associated With Nitrates
Menopausal Hot Flashes
Primary: Change From Baseline Hot Flash Frequency — -4.56; -4.02 Hot flashes per day — p=0.34
N/A N=187 Hypnosis For Hot Flashes Among Postmenopausal Women in a Randomized Clinical Trial
Hot Flashes
Primary: Hot Flash Frequency — 27.19; 68.26; 19.44; 62.32 hot flashes per week
Phase 4 N=29 Impact of Hot Flashes on Sleep and Mood Disturbance
Menopause · Depression · Hot Flashes
Primary: Percent Change in Wake After Sleep Onset (WASO) — 62 percent change — p=0.007
Phase 3 N=150 Oxybutynin Chloride in Managing Hot Flashes
Breast Carcinoma · Ductal Breast Carcinoma In Situ · Hot Flashes
Primary: Average Change in Hot Flash Activity Score From Baseline to Week 7 for Low Dose Oxybutynin vs Placebo and for High Dose Oxybutynin vs Placebo — -16.9; -10.6; -5.7 score…
N/A N=50 EMBr Wave for the Reduction of Hot Flashes in Women With a History of Breast Cancer
Breast Carcinoma · Breast Ductal Carcinoma In Situ · Breast Lobular Carcinoma In Situ
Primary: Device Usage
Phase 3 N=501 A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2
Hot Flashes
Primary: Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 4 — -3.72; -5.53; -6.26 VMS per day — p=<0.001
N/A N=250 A Mind-Body Intervention for Hot Flash Management
Hot Flashes · Postmenopausal Symptoms · Breast Cancer
Primary: Hot Flash Daily Diary — 88.7; 94.6; 41.3; 55.9 Hot Flash Score
Phase 3 N=527 A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause
Hot Flashes
Primary: Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 4 — -3.32; -5.19; -5.39 VMS per day — p=<0.001
Phase 3 N=943 Dose-Finding Safety and Efficacy Trial of Org50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (46101/P06459/MK-8265-012)
Menopause · Vasomotor Symptoms
Primary: Change From Baseline in Average Daily Frequency of Vasomotor Symptoms (Frequency Score A) at Week 4 — -3.9; -5.6; -6.0; -6.0 Number of events — p=<0.01
N/A N=27 Wrist Cooling for Hot Flashes Clinical Trial
Hot Flashes
Primary: Number and Severity of Hot Flashes — 1148; 692; 924; 1213 number of hot flashes
N/A N=38 Reducing the Experience of Menopausal Symptoms Through Temperature
Hot Flashes · Menopause
Primary: Hot Flash Diary — 9 number of hot flashes per week
Phase 3 N=945 Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001/P06472/MK-8265-013)
Postmenopausal Symptoms · Menopause · Vasomotor Symptoms
Primary: Change From Baseline in Average Daily Frequency of Moderate/Severe Vasomotor Symptoms (Frequency Score A) at Week 4 — 12.1; 12.2; 12.6; 12.3 Events per day — p=<0.01
Phase 3 N=189 Progesterone for Perimenopausal Night Sweats
Hot Flushes · Night Sweats
Primary: Vasomotor Symptoms (VMS)/ VMS Score - at 12 Weeks — 5.5; 7.1 Units of Vasomotor Symptom Score
Phase 2 N=356 A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)
Menopause · Hot Flashes
Primary: Co-Primary Efficacy Endpoint: Change From Baseline (CFB) in The Mean Frequency of Moderate to Severe Vasomotor Symptoms (VMS) at Week 4 — -4.2; -6.1; -7.2; -7.0 VMS per…
Phase 1 N=103 Study of Erenumab (AMG 334) in Women With Hot Flashes
Vasomotor Symptoms; Hot Flashes
Primary: Ratio of Week 4 to Baseline Average Number of Daily Moderate to Severe Hot Flashes — 0.35; 0.38 ratio — p=0.723
N/A N=8 HIRREM Hot Flashes Study
Vasomotor Symptoms · Hot Flashes · Menopause
Primary: Reduction in Hot Flash Severity Score Based on Diary Data — -0.39; -0.38 score on a scale
Phase 3 N=595 Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women
Hot Flashes
Primary: G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Frequency of Moderate to Severe Hot Flashes at Weeks 4 & 12 of the Efficacy Treatment Period…
N/A N=36 Vilazodone for Menopausal Hot Flashes
Hot Flushes
Primary: Daily Diary Ratings of Frequency of Hot Flashes — 3.65; 4.71 number of hot flashes — p=0.05
Phase 3 N=396 A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause
Vasomotor Symptoms Associated With Menopause · Hot Flashes
Primary: Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 4 (Assessed by Hot Flash Daily Diary [HFDD]). — 13.38; 14.26; -7.48; -4.37 Hot Flashes per day…
Phase 3 N=27 Pilot Study Comparing Hypnotherapy and Gabapentin for Hot Flashes.
Breast Cancer · Hot Flashes
Primary: Number of Daily Hot Flashes — 5; 4.5 daily hot flashes
Phase 2 N=87 Trial to Investigate the Effect of ESN364 in Early Postmenopausal Women Suffering From Hot Flashes
Hot Flashes
Primary: Change From Baseline to Week 12 in The Weekly General Hot Flash Score — -12.19; -26.51 score on a scale — p=<0.001
Phase 3 N=191 Pregabalin in Treating Women With Hot Flashes
Breast Cancer · Hot Flashes
Primary: Numerical Change From Baseline in Hot Flash Score at Treatment Week 6 (Positive Numbers to Represent Increases and Negative Numbers to Represent Decreases). — -9.6; -6.1…
Phase 3 N=1,831 A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause
Hot Flashes
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 391; 415; 389; 106 participants
Phase 3 N=400 A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)
Vasomotor Symptoms Associated With Menopause · Hot Flashes
Primary: Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 4 (Assessed by HFDD) — 14.66; 16.16; -8.58; -6.07 Hot Flashes per day — p=< 0.0001
Phase 3 N=628 A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 52 Weeks in Women Who Have Been Through the Menopause
Vasomotor Symptoms Associated With Menopause · Hot Flashes
Primary: Mean Change in Frequency of Moderate to Severe Hot Flashes (HFs) From Baseline to Week 12 (Assessed by Hot Flash Daily Diary [HFDD]) — 6.71; 6.81; -5.40; -3.50 Number of…
N/A N=205 MsFLASH-01: Escitalopram for Menopausal Symptoms in Midlife Women
Hot Flashes · Menopause · Vasomotor Symptoms
Primary: Daily Frequency of Hot Flashes Per Day Assessed by Prospective Daily Diaries — 9.88; 9.66 Hot flashes/day
Phase 4 N=60 Efficacy of Suvorexant in the Treatment of Hot Flash-associated Insomnia
Insomnia
Primary: Within-person Change in ISI Score — -8.1; -5.6 score on a scale